Uffe Heide-Jorgensen
Overview
Explore the profile of Uffe Heide-Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
718
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bonnesen K, Heide-Jorgensen U, Christensen D, Christiansen C, Lash T, Hennessy S, et al.
JAMA Intern Med
. 2025 Jan;
185(3):314-323.
PMID: 39836391
Importance: No large randomized clinical trial has directly compared empagliflozin with dapagliflozin, leaving their comparative effectiveness regarding kidney outcomes unknown. Objective: To compare kidney outcomes between initiation of empagliflozin vs...
2.
Vestergaard A, Jensen S, Heide-Jorgensen U, Ladefoged S, Birn H, Christiansen C
Clin Kidney J
. 2025 Jan;
18(1):sfae351.
PMID: 39781482
Background: Rates of chronic kidney disease (CKD) may change with ageing populations, rising metabolic and cardiovascular disease prevalence, increasing CKD awareness and new treatments. We examined sex-specific temporal trends in...
3.
Momen N, Ostergaard S, Heide-Jorgensen U, Sorensen H, McGrath J, Plana-Ripoll O
World Psychiatry
. 2024 Sep;
23(3):421-431.
PMID: 39279421
People with physical diseases are reported to be at elevated risk of subsequent mental disorders. However, previous studies have considered only a few pairs of conditions, or have reported only...
4.
Ostergaard S, Momen N, Heide-Jorgensen U, Plana-Ripoll O
JAMA Psychiatry
. 2024 Sep;
81(12):1198-1206.
PMID: 39230910
Importance: According to the World Health Organization, more than 700 000 individuals worldwide die by suicide each year. Medical conditions likely increase the risk of suicide. Objective: To (1) provide...
5.
Bonnesen K, Heide-Jorgensen U, Christensen D, Lash T, Hennessy S, Matthews A, et al.
Circulation
. 2024 Aug;
150(18):1401-1411.
PMID: 39206550
Background: Empagliflozin and dapagliflozin have proven cardiovascular benefits in people with type 2 diabetes at high cardiovascular risk, but their comparative effectiveness is unknown. Methods: This study used nationwide, population-based...
6.
Ziegler J, Morley K, Pilcher D, Bellomo R, Soares M, Salluh J, et al.
Am J Nephrol
. 2024 Jun;
55(5):539-550.
PMID: 38889694
Introduction: Acute kidney injury (AKI) requiring treatment with renal replacement therapy (RRT) is a common complication after admission to an intensive care unit (ICU) and is associated with significant morbidity...
7.
Jensen S, Heide-Jorgensen U, Gammelager H, Birn H, Christiansen C
Kidney Int Rep
. 2024 May;
9(4):817-829.
PMID: 38765592
Introduction: Acute kidney injury (AKI) is associated with chronic kidney disease (CKD) and cardiovascular disease (CVD); however, it is unclear whether AKI duration affects the long-term risks of CKD and...
8.
Liu P, Sawhney S, Heide-Jorgensen U, Quinn R, Jensen S, McLean A, et al.
BMJ
. 2024 Apr;
385:e078063.
PMID: 38621801
Objective: To train and test a super learner strategy for risk prediction of kidney failure and mortality in people with incident moderate to severe chronic kidney disease (stage G3b to...
9.
Kirkegard J, Gaber C, Heide-Jorgensen U, Fristrup C, Lund J, Cronin-Fenton D, et al.
J Natl Cancer Inst
. 2024 Feb;
116(7):1072-1079.
PMID: 38310365
Background: To estimate the causal effect of surgery vs chemotherapy on survival in patients with T1-3NxM0 pancreatic cancer in a rigorous framework addressing selection bias and immortal time bias. Methods:...
10.
Vestergaard A, Jensen S, Heide-Jorgensen U, Adelborg K, Birn H, Carrero J, et al.
Clin Kidney J
. 2024 Jan;
17(1):sfad252.
PMID: 38186872
Background: Direct oral anticoagulants (DOACs) are recommended as first-line treatment of atrial fibrillation. Whether DOAC use is associated with lower risks of kidney complications compared with vitamin K antagonists (VKAs)...